Operating CF
$4.34B
Capex
−$899.00M
Free Cash Flow
$3.44B
FCF Margin
+79.3%
Cash flow waterfall for Boston Scientific (BSX) — TTM through Q1 2026
Free cash flow: $3.44B
Cash flow breakdown for Boston Scientific (BSX) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $4.34B | $4.34B |
| Capital Expenditure | −$899.00M | $3.44B |
| Free Cash Flow | $3.44B | $3.44B |
| Acquisitions | −$1.88B | $1.56B |
| Other Investing | $45.00M | $1.61B |
| Net Debt Change | −$997.00M | $613.00M |
| Other Financing & FX | $90.00M | $703.00M |
| Net Cash Increase | $703.00M | $703.00M |
- Operating Cash Flow$4.34B
- Capital Expenditure−$899.00M
- Free Cash Flow$3.44B
- Acquisitions−$1.88B
- Other Investing$45.00M
- Net Debt Change−$997.00M
- Other Financing & FX$90.00M
- Net Cash Increase$703.00M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Boston Scientific (BSX) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement